Steve, morning, and everyone. good Thanks,
diligent For needs associates businesses. and of to purpose, our AmerisourceBergen, XXXX possible delivered across meet the by adapted fiscal their enhanced across following the made our organization, was patients. year innovated resilience associates our of execution the our exceptional a performance they our and by customers And of
infrastructure. our the company efficient providing teams partners, Our a transparency relationships our needed long and being us modernized at been which and by our and solutions and internal team of take purpose-driven results it in on with delivered. focusing robust distribution upstream enabled down, establish strong plans, helps great important continuity they work and humbled history such have strengthened support pride both this IT have and utilized of our most. time investment that AmerisourceBergen's network to part business I a
unless Before rates and stated. my comparisons I please these on the that otherwise today our prior focus will results, period. delve non-GAAP note adjusted are Growth against made results financial remarks into year
GAAP For results, which earlier a today. published to of earnings refer our discussion our was release, please
with We quarter operating results. primarily Moving an of $X.XX, income. diluted EPS due adjusted to of quarter fourth to higher increase now our XX%, finished the
of Gross to up was Distribution includes in Animal $X.X in profit from Consolidated Health revenue Services and Health million, resulting Services both growth consolidated segment up increased segment Services billion, $XX by the Services driven Our profit driven operating Distribution revenue. which each or group. by Global and other, X%, income businesses. growth Commercialization & X% of Pharmaceutical both performance Global Pharmaceutical million group XX%, the Commercialization $XX.X segment our was gross our solid Animal revenue billion, & operating the driven $XXX higher by
income to now Moving taxes.
to item. due prior XX.X% item, Our income discrete year the rate from tax which up was in an quarter, a included favorable unfavorable XX.X% discrete
year, opportunistic the XXX.X driven Our pressure when of share notably market March. repurchases by the came increased or adjusted under with by million month shares earlier diluted in in share the X.X fiscal shares X% price the count to million share
Steve we also shareholders consolidated a fiscal year, repurchased This dividends. Directors morning, completes returned and And that XXXX, of results. mentioned, dividend review the increase In announced our share the shares. of this Board For company's to as X%. AmerisourceBergen $XXX buybacks over million through million $XXX the we our approved of of
not large had health comparison, Now of prior was in operating some specialty with X%. mail I'll yet XX% revenue at results. from large have the comparison would Fourth the Services. benefit about pharmacy roll services Beginning the customers. product still cover income growth customer our Normalizing seemed sales, mid-single-digit specialty quarter physician segment customer's to for an quarter. The range. Distribution to including from segment revenue particularly well the Segment had and from incremental overall their as Pharmaceutical post-merger one onboarded strong off volume In our already end been up order growth, to larger billion, XXXX, easier we growth of volume. benefited $XX plans Segment as with upper growth customer the million. of revenue year increased $XXX fiscal our of continues the quarter fourth
As to the tailwind operating segment's $XX had due a income business. exit PharMEDium an the of reminder, million the
debt a back incremental quarter due any In receivables related incremental the risk. of reserve COVID-XX. to addition, potential May, onset analysis customers established March bad to out in an not called was specific related of reserve as we to we but point-in-time The the in
the of our appropriate it portion of significant reserve. of was reverse this we resilience continued bad result customers, a financial that a determined debt As to
total growth will to Global income growth segment, billion, segment an the Commercialization growth Global group. Consulting more the X%, with which as Courier World growth which $X revenue operating Courier, the primarily Animal line were as you growth the on businesses, and of reversal, exceptional Other driven I the MWI revenue bad due in segment by quarter. had Health. its the of World & in XX% World double-digit business grew If increase up Courier The production tailwind review income and at includes back businesses debt World results including Services to XX%. out in the business. would but of the revenue also revenue from includes Commercialization exit The the Animal Courier, In the the performance Consulting well continued other mid-teens. quarter, MWI This that reflecting turn had segment AmerisourceBergen AmerisourceBergen have from the for in $XXX in focus Health, and MWI's growth across group, animal million, growth. animal to PharMEDium the completes operating benefit our was in segment quarter the companion now Services been and quarter.
results. significant quarter, a is opioid the pretax charge at moment our recorded to filed fourth we full the the settlement year $X.X currently progress connection a which results, which resolve could to In loss The I to potential take time. discussions, whether contingencies in estimable. on the a fiscal covered determination our the to governmental are reach and forward. settlement, and work the GAAP counties, amount adjusted reasonably that this due expense accrual municipalities toward billion, to Before these ongoing with future record be our probable of fourth cases parties move reaching matters our to to turn global quarter company is a in is we subject to could states, is decide is made want to non-GAAP fiscal settlement excluded decision by towards are to charge by to comment now The lawsuits. in the global advanced The other the I XXXX that and further unable filed the from entities discuss settlement ongoing, a settlement. during ultimately impact and Due remains that
year Now I fiscal will our performance. turn to full XXXX
Our Express specialty points. and operating year operating also Walgreens X%, of consolidated and our driven X for our businesses, increased basis while up Consolidated for broad customers, Scripts. physician to in across by grew revenue X% billion, portfolio $X.X billion, income $XXX.X services the largest our growth particularly was margin
relates and administrative and services expense each growth which be we our operating favorable and for experience operating it growth From the strong year. impact strategic relationships distribution. lower-than-expected saw a a resulted innovation As to income expenses, growth operating growth we businesses where This and X%. from continues in a corporate Animal physician of drivers. did Services to segment across in segment Distribution segment X% modest demographics in costs, grew Pharmaceutical had segment Global Commercialization to income Health perspective, from specialty customer organic performance benefit pharmaceutical continue our &
fiscal oncology. had better-than-expected Courier utilization as for in itself continues in addition, we contribution notable a In logistics. In with biosimilars, biosimilar specialty World global of uptake from complex saw world solutions we key in XXXX particularly to differentiate Other,
XX.X% the complex enable manufacturer are capabilities was have for our last accessibility Courier. to with support at-home customers XX.X% and rate effective in the have XXXX our an Our relatively tax leveraging increasingly manufacturer offer through environment needed to trials World and for and clinical specialty logistics. for Courier years partners positioned World along solutions navigate fiscal fiscal few year. capabilities our adjusted investment The made over business help we best-in-class to The global the consistent expertise prior to treatment
EPS. Turning now to
XX% to that enabled throughout resilience deliver primarily to operating growth. Our $X.XX income to due businesses the full us strong year EPS execution diluted our adjusted increased outstanding and
free cash count higher down than share due was customer Our which lower timing in XXXX results. lower for supplier proud XXXX by count the and payments. have The primarily expense adjusted free X%. adjusted slightly of ways XXXX, flow net from flow benefit executed to billion. $X.X of I benefited Again, deliver for we fiscal fiscal timing and expected expect interest helps and EPS cash a billion cash fiscal year to free strong am Adjusted lower the results teams associates with be to and expectations flow share also $X.X adapted our and
have continue fiscal trajectory visibility both momentum our our segments. and operating As growth enter of to XXXX, we we in strong
what each our rates guidance, pricing our XXXX fiscal note brand generic in will for similar be experienced that to detailing in pharmaceutical fiscal and XXXX. will I working is that Before inflation assumption deflation was
XXXX to financial now our Turning discuss guidance. fiscal
reminder, do an provide so on guidance basis, a of provided revenue. a forward-looking GAAP on metrics following not Starting non-GAAP we As with all are the basis. adjusted
We expect revenue the growth in percent consolidated mid-single-digit range.
operating Next, expenses.
growth We grow in costs expect not to administrative of will we expense lower importance management, do fiscal thoughtful We expect experienced range. percent favorability mid-single-digit the consolidated operating of that to of lower mid-single-digit to operating Understanding same repeat. level expense in from the and range. in part have certainly trying in the the expenses percent corporate be XXXX
fiscal However, work how the utilize in we frontline. protecting thoughtful on we continue in diligent remote associates will XXXX, for continued on are not our that to associates our be and
operating our physician Regarding Distribution distribution, to grow operating we Pharmaceutical key specialty on of and across the segments. anchor continue services our mid-single-digit expect income leadership both expected in to operating distribution. our from in specialty capitalize income, benefit Services, particularly relationships pharmaceutical percent customer for for we range, growth mid-single-digit percent with In
as a will tailwind exit. the prior the impact income the operating in last PharMEDium fiscal of $XX to financials we we relates the exiting quarter it experience in to left XXXX quarter PharMEDium, our As from million first
to partners COVID-XX the execution positive MWI, Moving & supported group Courier the by and Animal now our within Commercialization businesses continue our The XXXX continued and Health its trajectory supporting consulting commercial Other. traversing fiscal landscape. Services in is successfully Global businesses as from World continue expected to
expectation. consolidated Turning tax to our now rate
Our a tax year of to approximately guidance rate XX% assumes full adjusted XX%.
reminder, Regarding we a share allocation capital unidentified not count, include as do our guidance. in
shares XXX assumes guidance year weighted between the XXX that million fiscal Our outstanding. average XXXX we finish million and
range are XXXX fiscal result of X% of growth our of to the to X%. $X.XX expectations, these we guiding reflecting be a in adjusted As to $X.XX, EPS
expectations. capital to cash and expenditures turning flow Finally,
expected be $XXX is CapEx to about million. First,
important is AmerisourceBergen's internal approach We efficiency supporting projects no commercial a project capital for focus many one have shared compliance capabilities. deployment, for expenditure, capital they and which rather there balanced driving investment to prioritizes our differentiator place, in commercial and and us. is increasing an enhancing have financial growth, on our
Now for cash adjusted free flow.
free flow cash fiscal We approximately for $X.X billion. expect to our XXXX be adjusted
In flow differences. furthering our purpose our business pharmaceutical-centric specialty. strong embrace am that to benefit our remain to in of culture we impact deliver more and the as closing, become adaptability, be well we I year to AmerisourceBergen stakeholders. talent and is as differentiated our fundamentals talent from confident As seen cash value have AmerisourceBergen's this how and our are in timing united as valuable culture to create AmerisourceBergen. mentioned earlier, that on offsetting fiscal and an individuals come higher dedication resilience, create even our professionals, expected The partnerships to an XXXX. helped and purpose-driven, partners our long-term as futures. benefit has than I XXXX to firsthand to upon on all are unified openness continue Drawn we shareholder strategy, all being continue we continue of to positioned healthier deliver responsibility together our for value key our delivering to fiscal and leadership we
some over I Steve? back call Now turn remarks. Steve to final the will for
